A Double-Blind, Randomized, Placebo Controlled Study of the Efficacy and Safety of Three Doses of Orvepitant in Subjects With Chronic Refractory Cough
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Orvepitant (Primary)
- Indications Cough
- Focus Therapeutic Use
- Acronyms volcano-2
- Sponsors NeRRe Therapeutics
- 01 Jun 2017 Status changed from not yet recruiting to recruiting.
- 27 Mar 2017 Planned initiation date changed from 1 Apr 2017 to 8 May 2017.
- 19 Dec 2016 New trial record